Skip to main content
Download PDF

Monoclonal Antibodies in Oncology and their Effect on Arterial Stiffness — A Systematic Review

Artery Research volume 26, pages 137–142 (2020)Cite this article

Abstract

Introduction

Malignancies are the second leading cause of death worldwide. Treatment Monoclonal Antibody (MAbs)-based treatment of cancer has been established as one of the most successful therapeutic strategies in the last 20 years; however, there is a growing concern about the effects of these agents on patients’ cardiovascular profile.

Areas Covered

In this manuscript we summarize current evidence regarding MAb effects on arterial stiffness, which is an recognised biomarker of cardiovascular risk. For this purpose, we explored two bibliographic databases [PubMed, Scopus] and one full-text database (Google-Scholar) for all publications published on MAbs’ effects on arterial stiffness until December 2019. Only few of the monoclonal antibody agents used in oncology have been investigated as per their effects on arterial properties and this limited evidence suggests that cancer therapy with monoclonal antibodies demonstrates either a temporary or long-term increase in arterial stiffness.

Discussion

It seems that by targeting ‘checkpoints’ in cancer genesis, anticancer MAbs also affects vascular properties causing endothelial dysfunction and arterial stiffness. Furthermore, several MAbs cause hypertension and may as a result increase pulse wave velocity. On the other hand, MAbs that target inflammatory cytokines seem to improve cardiovascular survival however, their effect on arterial stiffness is yet to be investigated. Further research is warranted in order to elucidate the biochemical pathways, clinical implications and potential reversibility of monoclonal antibody chemotherapy-induced vascular dysfunction.

References

  1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://www.globocan.iarc.fr [Last accessed on 2016 Dec 13].

  2. Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J 2013;34:1102–11.

    Google Scholar 

  3. Groarke JD, Nohria A. Anthracycline cardiotoxicity: a new paradigm for an old classic. Circulation 2015;131:1946–9.

    Google Scholar 

  4. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am College Cardiol 2010;55:1318–27.

    Google Scholar 

  5. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006;27:2588–605.

    Google Scholar 

  6. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Abridged version of the expert consensus document on arterial stiffness. Artery Res 2007;1:2–12.

    Google Scholar 

  7. Vlachopoulos C, Xaplanteris P, Aboyans V, Brodmann M, Cífková R, Cosentino F, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis 2015;241:507–32.

    Google Scholar 

  8. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al, 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J 2018;39:3021–104.

  9. Vlachopoulos C, Terentes-Printzios D, Laurent S, Nilsson PM, Protogerou AD, Aznaouridis K, et al. Association of estimated pulse wave velocity with survival: a secondary analysis of SPRINT. JAMA Netw Open 2019;2:e1912831.

  10. Wong SF. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther 2005;27:684–94.

    Google Scholar 

  11. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004;59:21–6.

    Google Scholar 

  12. Ménard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003;22:6570–8.

    Google Scholar 

  13. Herceptin [package insert]. South San Francisco, California: Genentech I; 2006.

  14. Yersal Ö, Eryilmaz U, Akdam H, Meydan N, Barutca S. Arterial stiffness in breast cancer patients treated with anthracycline and trastuzumab-based regimens. Cardiol Res Pract 2018;2018:5352914.

    Google Scholar 

  15. Filatova AY, Vitsenya MV, Potekhina AV, Gavryushina SV, Pylaeva EA, Pestova AB, et al. Atherosclerosis of brachiocephalic arteries and arterial stiffness in patients with breast cancer. Kardiologiia 2019;59:43–52 [Article in Russian].

    Google Scholar 

  16. Grover S, Lou PW, Bradbrook C, Cheong K, Kotasek D, Leong DP, et al. Early and late changes in markers of aortic stiffness with breast cancer therapy. Intern Med J 2015;45:140–7.

    Google Scholar 

  17. Gemmete JJ, Mukherji SK. Panitumumab (vectibix). AJNR Am J Neuroradiol 2011;32:1002–3.

    Google Scholar 

  18. Res E, Kyvelou SM, Vlachopoulos C, Manousou K, Tousoulis D, Stefanadis C, et al. Metastatic malignancies and the effect on arterial stiffness and blood pressure levels: the possible role of chemotherapy. Onco Targets Ther 2018;11:6785–93.

    Google Scholar 

  19. Naeim F, Rao P, Song S, Phan R. Principles of immunophenotyping. In: Atlas of Hematopathology. 2nd ed. San Diego, CA: Academic Press; 2018.

  20. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004;199:1659–69.

    Google Scholar 

  21. Cerny T, Borisch B, Introna M, Johnson P, Rose A. Mechanism of action of rituximab. Anticancer Drugs 2002;13:S3–S10.

    Google Scholar 

  22. Shimizu N, Nakamura S, Kawagoe N, Oka R, Watanabe Y, Tanaka S, et al. Rituximab (R)-CHOP therapy has progressed arteriosclerosis with an elevation of Von Willebrand factor (vWF) in patients with malignant lymphoma. Blood 2018;132:5380.

    Google Scholar 

  23. Novikova DS, Popkova TV, Lukina GV, Luchikhina EL, Karateev DE, Volkov AV, et al. The effects of rituximab on lipids, arterial stiffness and carotid intima-media thickness in rheumatoid arthritis. J Korean Med Sci 2016;31:202–7.

    Google Scholar 

  24. Mathieu S, Pereira B, Dubost JJ, Lusson JR, Soubrier M. No significant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment. Rheumatology (Oxford) 2012;51:1107–11.

    Google Scholar 

  25. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–42.

    Google Scholar 

  26. Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539–44.

    Google Scholar 

  27. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542–50.

    Google Scholar 

  28. Steeghs N, Rabelink TJ, op ’t Roodt J, Batman E, Cluitmans FHM, Weijl NI, et al. Reversibility of capillary density after discontinuation of bevacizumab treatment. Ann Oncol 2010;21:1100–5.

    Google Scholar 

  29. Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A, et al. Vascular toxicities of cancer therapies: the old and the new–an evolving avenue. Circulation 2016;133:1272–89.

    Google Scholar 

  30. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666–76.

    Google Scholar 

  31. Sandoo A, Kitas GD, Carmichael AR. Endothelial dysfunction as a determinant of trastuzumab-mediated cardiotoxicity in patients with breast cancer. Anticancer Res 2014;34:1147–51.

    Google Scholar 

  32. Kapustin AN, Davies JD, Reynolds JL, McNair R, Jones GT, Sidibe A, et al. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circ Res 2011;109:e1–e12.

    Google Scholar 

  33. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999;340:115–26.

    Google Scholar 

  34. Vlachopoulos C, Dima I, Aznaouridis K, Vasiliadou C, Ioakeimidis N, Aggeli C, et al. Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation 2005;112:2193–200.

    Google Scholar 

  35. Mäki-Petäjä KM, Wilkinson IB. Arterial stiffness and inflammation — a potential target for a drug therapy. Artery Res 2010;4:99–107.

    Google Scholar 

  36. Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 2017;390:1833–42.

    Google Scholar 

  37. Tabata N, Sueta D, Yamamoto E, Takashio S, Arima Y, Araki S, et al. A retrospective study of arterial stiffness and subsequent clinical outcomes in cancer patients undergoing percutaneous coronary intervention. J Hypertens 2019;37:754–64.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 1st Department of Cardiology, Hippokration Hospital, Athens, Greece

    Eirini Solomou, Konstantinos Aznaouridis, Dimitrios Terentes-Printzios, Maria Drakopoulou, Konstantinos Toutouzas, Dimitris Tousoulis & Charalambos Vlachopoulos

Authors
  1. Eirini Solomou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Konstantinos Aznaouridis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dimitrios Terentes-Printzios
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maria Drakopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Konstantinos Toutouzas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dimitris Tousoulis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Charalambos Vlachopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charalambos Vlachopoulos.

Additional information

Peer review under responsibility of the Association for Research into Arterial Structure and Physiology

Rights and permissions

This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Solomou, E., Aznaouridis, K., Terentes-Printzios, D. et al. Monoclonal Antibodies in Oncology and their Effect on Arterial Stiffness — A Systematic Review. Artery Res 26, 137–142 (2020). https://doi.org/10.2991/artres.k.200323.001

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2991/artres.k.200323.001

Keywords

Artery Research

ISSN: 1876-4401

Contact us